Drug Profile
TPC 144
Alternative Names: TPC-144Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for preclinical development in Cancer in Japan (PO)
- 29 Nov 2016 Preclinical trials in Cancer in Japan before November 2016 (PO)
- 29 Nov 2016 Pharmacodynamics data from a preclinical study presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics-2016 (EORTC-NCI-AACR-2016)